Background: Seizures are rare during repetitive transcranial magnetic stimulation (rTMS) treatment, but estimating risk is difficult because of study heterogeneity and sampling limitations. Moreover, there are few studies comparing rates between device manufacturers.
Objective: The objective of this study was to calculate rTMS seizure rates across various FDA-cleared devices in naturalistic clinical settings.
Methods: In July and August 2018, approximately 500 members of the Clinical TMS Society (CTMSS) were electronically surveyed about seizures in their practices. Seizures were distinguished from non-seizures by a remote semi-structured interview with a Board-certified neurologist and Co-Chair of the CTMSS Standards Committee. Exact Poisson calculations were used to estimate seizure rates and confidence intervals across the four most widely used manufacturers.
Results: The survey was completed by 134 members, with 9 responses excluded because of data inconsistencies. In total, 18 seizures were reported in 586,656 sessions and 25,526 patients across all device manufacturers. The overall seizure rate was 0.31 (95% CI: 0.18, 0.48) per 10,000 sessions, and 0.71 (95% CI: 0.42, 1.11) per 1000 patients. The Brainsway H-coil seizure rate of 5.56 per 1000 patients (95% CI: 2.77,9.95) was significantly higher (p < 0.001) than the three most widely used figure- 8 coil devices' combined seizure rate of 0.14 per 1000 patients (95% CI: 0.01, 0.51).
Conclusion: The absolute risk of a seizure with rTMS is low, but generic Brainsway H-coil treatment appears to be associated with a higher relative risk than generic figure- 8 coil treatment. Well-designed prospective studies are warranted to further investigate this risk.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.brs.2021.05.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Medical & Socioeconomic Risk Factors Associated with Lack of Neurodevelopmental Evaluation Following Neonatal Cardiac Surgery.
Pediatr Cardiol
January 2025
Division of Cardiac Critical Care, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Neonates with congenital heart disease (CHD) who undergo cardiopulmonary bypass (CPB) are at high-risk for unfavorable neurodevelopmental (ND) outcomes and are recommended for ND evaluation (NDE); however, poor rates have been reported. We aimed to identify risk factors associated with lack of NDE. This single-center retrospective observational study included neonates < 30 days old who underwent CPB and survived to discharge between 2012 and 2018.
View Article and Find Full Text PDFPerformance validity tests in people with epilepsy: A review of the literature.
Seizure
December 2024
University College Hospital, London, UK; UCL Queen Square Institute of Neurology: Department of Clinical and Experimental Epilepsy, London WC1N 3BG, UK. Electronic address:
Objective: Professional bodies recommend the use of performance validity tests (PVTs) to aid the interpretation of scores obtained in neuropsychological assessments, but base rates of failure differ according to neurological diagnosis and the associated impairments. This review summarises the PVT literature in people with epilepsy with the aim of establishing base rates of PVT failure and the factors associated with PVT performance in this population.
Methods: Ovid and PubMed databases were searched for studies reporting PVT test performance in people with epilepsy.
Treatment of Seizures in People with Intellectual Disability.
CNS Drugs
January 2025
Cornwall Intellectual Disability Equitable Research (CIDER), University of Plymouth, Truro, England.
There is a synergistic relationship between epilepsy and intellectual disability (ID), and the approach to managing people with these conditions needs to be holistic. Epilepsy is the main co-morbidity associated with ID, and clinical presentation tends to be complex, associated with higher rates of treatment resistance, multi-morbidity and premature mortality. Despite this relationship, there is limited level 1 evidence to inform treatment choice for this vulnerable population.
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
Department of Bioengineering, University of California, Los Angeles, CA, USA, Los Angeles, CA, USA.
Background: Alzheimer's disease (AD) is characterized by cognitive decline and increased seizure susceptibility due to brain damage and neural disruptions. This study examines the relationship between cognitive deterioration and seizure pathology in hAPP-J20 transgenic Alzheimer's mice, a model known for amyloid plaque deposition and heightened seizure activity.
Method: We observed hAPP-J20 mice aged 8 to 28 weeks using long-term wireless telemetry to assess hippocampal local field potential, sampled at 2 kHz.
Efficacy and tolerability of lacosamide in pediatric and young adult epilepsy patients with severe motor and intellectual disabilities.
Neuropediatrics
December 2024
Pediatrics, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Objective: Epilepsy is common among patients with severe motor and intellectual disability (SMID) patients, often taking a prolonged and intractable course. Lacosamide (LCM) is widely used to treat epilepsy in both adults and children. We assess the efficacy and tolerability of LCM among pediatric and young adult epilepsy patients with SMID who suffer from intractable seizures.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!